Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV) — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV) — Stella

Recruiting

Back to Hepatocellular Carcinoma trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Singapore

Singapore General Hospital, Singapore

Key details

Phase

Early testing

Sponsor

Lion TCR Pte. Ltd.

Enrollment target

~10 participants

Started

May 2022

Primary completion

July 2026

Age range

21 Years – 75 Years

Last updated November 2023

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov